Wang ML, Blum KA, Martin P, et al. Prepare to become a physician, build your knowledge, lead a health care organization, and advance your career with NEJM Group information and services. Owen RG, Treon SP, Al-Katib A, et al. The median duration of response was not reached (range, 1.9 to 36.4 months) among the 54 patients who had at least a partial response in the ibrutinib–rituximab group and was 21.2 months (range, 4.6 to 25.8) among the 24 patients with at least a partial response in the placebo–rituximab group. This article was published on June 1, 2018, at NEJM.org. Patients were enrolled at 45 sites in 9 countries between July 2014 and January 2016. Leuk Lymphoma 2010;51:1779-1792. Blood 2015;126:739-745. Among patients with Waldenström’s macroglobulinemia, the use of ibrutinib–rituximab resulted in significantly higher rates of progression-free survival than the use of placebo–rituximab, both among those who had received no previous treatment and among those with disease recurrence. After 4 weeks of treatment, the median IgM level was reduced from baseline by 56% with ibrutinib–rituximab as compared with an increase of 6% with placebo–rituximab (Fig. Interferon is a cytokine that can be made in the lab and given to patients. We couldn’t do what we do without our volunteers and donors. Events of grade 3 or higher that occurred more frequently with ibrutinib–rituximab than with placebo–rituximab included atrial fibrillation (12% vs. 1%) and hypertension (13% vs. 4%); those that occurred less frequently included infusion reactions (1% vs. 16%) and any grade of IgM flare (8% vs. 47%). 2 Clarke DriveSuite 100Cranbury, NJ 08512. 17. Concise summaries and expert physician commentary that busy clinicians need to enhance patient care. We’ve invested more than $4.9 billion in cancer research since 1946, all to find more – and better – treatments, uncover factors that may cause cancer, and improve cancer patients’ quality of life. Responses were based on modified consensus criteria from the sixth International Workshop on Waldenström’s Macroglobulinemia (Table S2 in the Supplementary Appendix). Patients continued to receive ibrutinib for a median of 25.8 months (range, 1.0 to 37.2) and placebo for a median of 15.5 months (range, 0.4 to 34.3), so the collection period for safety data was longer in the ibrutinib–rituximab group. A low rate of histologic transformation to diffuse large B-cell lymphoma was observed (in two patients in the ibrutinib–rituximab group and no patients in the placebo–rituximab group). In the overall population, the ORR was 92% with the ibrutinib combination versus 47% with rituximab alone (P <.0001). Dimopoulos MA, García-Sanz R, Gavriatopoulou M, et al. Available Every Minute of Every Day. Anti-CD20 and B-cell receptor-mediated growth inhibition and apoptosis: a preclinical study of ibrutinib and rituximab combination therapy in mantle cell lymphoma in vitro and in vivo. From basic information about cancer and its causes to in-depth information on specific cancer types – including risk factors, early detection, diagnosis, and treatment options – you’ll find it here. Owen RG, Pratt G, Auer RL, et al. Blood 2013;122:3276-3282. Together, we’re making a difference – and you can, too. Immunomodulating drugs (IMiDs) are thought to work against certain cancers by boosting parts of your immune system, although exactly how they work is not clear. Adverse events of any grade that were substantially more frequent with ibrutinib–rituximab than with placebo–rituximab were diarrhea, arthralgia, and nausea, and those that were less frequent were IgM flare, infusion-related reactions, fatigue, asthenia, anemia, and headache (Table 2). © 2020 American Cancer Society, Inc. All rights reserved. Pomalidomide (Pomalyst) is a newer IMiD that generally cause less severe side effects than thalidomide. Zhang L, Zhang H, Zhao D, et al. Mazzucchelli M., Frustaci A.M., Deodato M., Cairoli R., Tedeschi A. Waldenstrom’s macroglobulinemia: an update. Adverse events led to a dose reduction of ibrutinib in 13 patients (Table S5 in the Supplementary Appendix). Kinase inhibitor ibrutinib to prevent cytokine-release syndrome after anti-CD19 chimeric antigen receptor T cells for B-cell neoplasms. Recent Advances in Small-Cell Lung Cancer, OncLive Events Scientific Interchange Workshop Series. The rate of major response was higher with ibrutinib–rituximab than with placebo–rituximab (72% vs. 32%, P<0.001). Clinical Practice Guidelines in Oncology: Waldenstrom’s macroglobulinemia/Lymphoplasmacytic lymphoma. Central nervous system involvement by Waldenström macroglobulinaemia (Bing-Neel syndrome): a multi-institutional retrospective study. ), and Peter MacCallum Cancer Centre and St. Vincent’s Hospital, Melbourne, VIC (C.T.) All rights reserved. This drug is more commonly used to treat patients with chronic lymphocytic leukemia, but it also helps some patients with WM. Address reprint requests to Dr. Dimopoulos at the Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Alexandra Hospital, Athens 11528, Greece, or at [email protected]. In the experimental arm, patients received ibrutinib for a median of 25.8 months (range, 1.0-37.2). Results of a randomized trial of chlorambucil versus fludarabine for patients with untreated Waldenström macroglobulinemia, marginal zone lymphoma, or lymphoplasmacytic lymphoma. N Engl J Med 2015;372:1430-1440. S2A in the Supplementary Appendix).